Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 72603-425

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 72603-425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Pem Hansoh Ns Fig1)

Figure 1 (Pem Hansoh Ns Fig1)
A Kaplan-Meier survival curve chart depicting overall survival percentage over time in months. Two treatment arms are compared: A+P+C (black line) and A+C (gray line). The chart includes a risk table below showing the number of patients at risk at various time points (0, 6, 12, 18, 24, 30, 36, 42 months) for each treatment arm.*
FDA Label Image

Figure 2 (Pem Hansoh Ns Fig2)

Figure 2 (Pem Hansoh Ns Fig2)
A survival probability curve chart comparing Pemetrexed plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) over a 30-month survival time period. The chart includes survival probabilities on the vertical axis and time in months on the horizontal axis, along with a table showing the number of patients at risk for both treatment groups at various time points.*
FDA Label Image

Figure 3 (Pem Hansoh Ns Fig3)

Figure 3 (Pem Hansoh Ns Fig3)
A Kaplan-Meier survival curve chart comparing survival probability over time (in months) for two chemotherapy regimens: Pemetrexed plus Cisplatin (PC) represented by a solid line, and Gemcitabine plus Cisplatin (GC) shown as a dotted line. Below the graph, a table lists the number of patients at risk at various time points up to 30 months for each treatment group.*
FDA Label Image

Figure 4 (Pem Hansoh Ns Fig4)

Figure 4 (Pem Hansoh Ns Fig4)
A Kaplan-Meier survival curve chart comparing survival probability over time (up to 30 months) between two treatments: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes survival probabilities on the vertical axis and survival time in months on the horizontal axis, with a table showing the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Figure 5 (Pem Hansoh Ns Fig5)

Figure 5 (Pem Hansoh Ns Fig5)
A Kaplan-Meier survival curve chart comparing survival probability over time (months) between Pemetrexed and placebo groups. The graph includes survival probability on the y-axis and survival time in months on the x-axis. Patient numbers at risk are shown below the chart for both groups across time points.*
FDA Label Image

Figure 6 (Pem Hansoh Ns Fig6)

Figure 6 (Pem Hansoh Ns Fig6)
A Kaplan-Meier survival curve graph comparing survival probability over time (in months) between patients treated with Pemetrexed and a placebo. The solid line represents Pemetrexed, and the dotted line represents placebo. Below the graph, the number of patients at risk is listed for each group over time.*
FDA Label Image

Figure 7 (Pem Hansoh Ns Fig7)

Figure 7 (Pem Hansoh Ns Fig7)
A Kaplan-Meier survival curve comparing survival probability over time in months for patients treated with Pemetrexed injection versus placebo. The solid line represents the Pemetrexed group, and the dotted line represents the placebo group. A table below shows the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 8 (Pem Hansoh Ns Fig8)

Figure 8 (Pem Hansoh Ns Fig8)
A survival probability curve comparing Pemetrexed and placebo over time in months. The chart shows survival probability on the vertical axis and survival time in months on the horizontal axis, with a patient risk table below indicating numbers at risk at various months for each group.*
FDA Label Image

Figure 9 (Pem Hansoh Ns Fig9)

Figure 9 (Pem Hansoh Ns Fig9)
A survival probability Kaplan-Meier curve comparing Pemetrexed plus Cisplatin versus Cisplatin alone over survival time in months. The graph includes two lines showing the survival probabilities and a table indicating the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Structural Formula (Pem Hansoh Ns Struct)

Structural Formula (Pem Hansoh Ns Struct)
Chemical structure of Pemetrexed disodium heptahydrate showing its molecular components, including amino groups, carboxylate sodium salts, and aromatic rings.*
FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp Northstar 100 mg Carton (Peme Hansoh 100mg Ns Carton)

Principal Display Panel – Pemetrexed For Injection, Usp Northstar 100 mg Carton (Peme Hansoh 100mg Ns Carton)
Packaging label for Pemetrexed for Injection USP, 100 mg per vial, single-dose vial for intravenous use only. The lyophilized powder for injection is labeled with the National Drug Code 72603-325-01 and manufactured by NorthStar Rx LLC with manufacturing in China. The label includes reconstitution instructions, storage conditions, and a warning that the product is a cytotoxic agent and preservative-free, without natural rubber latex in the container closure.*
FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp 100 mg Northstar Vial Label (Peme Hansoh 100mg Ns Cont)

Principal Display Panel – Pemetrexed For Injection, Usp 100 mg Northstar Vial Label (Peme Hansoh 100mg Ns Cont)
Pemetrexed for Injection USP 100 mg per vial lyophilized powder label for intravenous use only. The label indicates it is a single-dose vial and a cytotoxic agent. The labeler is NorthStar Rx LLC.*
FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp Northstar 500 mg Carton (Peme Hansoh 500mg Ns Carton)

Principal Display Panel – Pemetrexed For Injection, Usp Northstar 500 mg Carton (Peme Hansoh 500mg Ns Carton)
Carton label for Pemetrexed for Injection USP, 500 mg per vial, powder, lyophilized for solution, for intravenous use only. The label indicates a single-dose vial and includes directions for reconstitution and storage. It is manufactured by NorthStar Rx LLC. The design features a blue and white color scheme with dosage strength prominently displayed.*
FDA Label Image

Principal Display Panel – Pemetrexed For Injection, Usp Northstar 500 mg Vial Label (Peme Hansoh 500mg Ns Cont)

Principal Display Panel – Pemetrexed For Injection, Usp Northstar 500 mg Vial Label (Peme Hansoh 500mg Ns Cont)
Label for Pemetrexed for Injection USP, 500 mg per vial, an intravenous lyophilized powder for injection. The label includes a caution indicating it is a cytotoxic agent, the NDC number 72603-425-01, and the labeler NorthStar RxLLC. Instructions for storage, dosage, and handling are printed along with a barcode and manufacturing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.